Intrastriatal grafts of fetal ganglionic eminences (GE) can reverse symptoms of striatal lesions in animal models of Huntington's disease. On the other hand, neurotrophic factors have been shown to protect host striatal neurons from ongoing degeneration. Neurotrophic gene transfer into GE prior to grafting could combine the benefits of striatal neuron replacement and in situ delivery of neurotrophic factors. Here we evaluate the potency of recombinant adeno-associated viruses (rAAV) as vectors for gene delivery into rat embryonic (E15) GE using the eGFP reporter gene under the control of the strong cytomegalovirus (CMV) promoter. We observed a very efficient expression of the eGFP reporter gene in organotypic cultures of GE infected with rAAV serotype 1 from 4 days until at least 4 weeks postinfection. In contrast, transduction was low and absent when using serotype 2 and serotype 5 rAAV, respectively. Two months after transplantation of rAAV2/1-infected embryonic GE in adult rat striatum, more than 20% of grafted cells expressed eGFP. The majority of transduced cells in the graft were neurons as indicated by colabeling of GFP-immunoreactive cells with the NeuN marker. Our study suggests that GE transduced by rAAV-serotype 1 vectors could be an interesting tool to mediate efficient expression of a gene coding a neurotrophic factor in Huntington's disease.
INTRODUCTION
rons can reverse a number of symptoms and reestablish the functional connections between afferent axons and the grafted cells (9). Moreover, clinical benefits have Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder involving primary been demonstrated in patients after striatal grafts (3, 17) . However, after 6 years, motor and metabolic benefits GABAergic medium spiny projection neurons in the striatum (26) and cerebral cortex (27) . The disease is decreased (4), presumably because the patient's neurons continue to degenerate. characterized by devastating motor, cognitive, and psychiatric disturbances, which usually appear in adult life Experimental studies, in vitro (24) as well as in animal models (1) , demonstrated significant benefits of and progress over one to two decades. Huntingtin, the gene causing HD, has been cloned in 1993 and the muta-neurotrophic factors (NF). While neurotrophic factors have shown promising results, the method of their deliv-tion identified as an unstable (CAG)n repeat in the coding region of the protein (30) . Although the mechanisms ery may be critical in establishing potent neuroprotection. Indeed, systemic administration of NF is associated accounting for the selective striatal degeneration are intensively studied, to date pharmacological therapies with important side effects and a low detectable concentration in the central parenchyma (20) . These data have show low efficiency and do not provide reconstruction of brain neural circuit or prevent progression of the dis-led to the investigation of delivery systems that allow continuous administration of NF directly into the brain ease (12, 13, 28, 31) . In various experimental animal models of HD, intrastriatal implantation of striatal fetal neu-(mechanical minipumps, gene delivery) (2, 5, 15, 21) . In-trastriatal administration of glial cell line-derived neuro-Preparation of Ganglionic Eminences Cell Suspensions trophic factor (GDNF) (15) and ciliary neurotrophic fac-Dissection of the lateral (LGE) and medial (MGE) tor (CNTF) (21) has been shown to rescue striatal neurons ganglionic eminences from E15 embryos was performed from quinolinic acid-induced and 3-nitropropionic acid in HBSS.
LGE and MGE fragments from both hemidamage, respectively, suggesting that increased neurospheres of all embryos were pooled. Fragments (ϳ1 trophic factor expression may prevent or reduce neumm 3 ) were infected with rAAV2/1-CMV-GFP vectors ronal loss in the HD brain. A combined substitutive and for 2 h at 37°C. Cell suspensions were prepared accordneuroprotective therapy could enhance graft survival as ing to a protocol described by Watts and collaborators well as halt or slow down the host's neuron degeneration.
(33) with minor modifications. Fragments were washed In the present study, we tested the efficiency of rein isotonic saline containing 0.6% glucose and trypsincombinant adeno-associated viruses (rAAV) as vectors ized for 20 min at 37°C in saline containing 0.1% trypfor gene transfer into striatal grafts. Recombinant AAV sin (Worthington) and 0.05% DNAase. Fragments were lacks all viral genes and mediates long-term gene exthen mechanically dissociated in a 1:1 mixture of triturapression in vivo in adult neurons with a low and trantion medium [1% bovine serum albumin (BSA; Sigma), sient immune response and no toxicity (23). Moreover, 0.001% deoxyribonuclease (Sigma), 0.5% soybean tryp-rAAVs have been used to deliver therapeutical genes in sin inhibitor in saline (Sigma), and Dulbecco's minimal patients without toxicity (19) . Recently, several different essential medium (DMEM; Life Technologies) suppleserotypes of AAV have been used to derive vectors with mented with 10% fetal calf serum (Biowhitakker)]. The varying efficiencies in different tissues (25) . AAV-1 cells were centrifuged at 800 rpm for 10 min and the and -5 have been shown to be particularly efficient in pellet was resuspended in a volume of 8 µl per eminence adult rat striatum (6). However, no data are available of trituration medium. The cell survival rate was deterabout the gene transfer efficiency of rAAVs in fetal strimined by trypan blue dye exclusion using a Bürker atum. Therefore, we evaluated the gene delivery potenchamber and was always higher than 90%. tial of vectors based on AAV serotype 1, 2, and 5 into Organotypic Cultures rat embryonic ganglionic eminences (GE), with the aim to improve the survival of grafted striatal neurons and
LGE and MGE fragments from four to five fetuses to protect the host striatum neurons from ongoing dewere infected with 10 9 viral particles of rAAV2/1-CMVgeneration by delivering genes coding for NF. eGFP, rAAV2/2-CMV-eGFP, or rAAV2/5-CMV-eGFP for 2 h at 4°C. Fragments were then transferred on the MATERIALS AND METHODS membrane of Transwells (Costar) and maintained with 1.1 ml serum-free minimum essential medium (MEM;
Recombinant AAV Vectors
Life Technologies, Belgium) containing 1% glucose, 5 The rAAV2/1-CMV-eGFP, rAAV2/2-CMV-eGFP, mM Tris-HCl, pH 7.4, 100 µl/ml BSA, 100 µl/ml tranand rAAV2/5-CMV-eGFP were produced at the "GVPN" ferrin, 16 ng/ml putrescin, 40 ng/ml Na-selenium, 30 ng/ (Laboratoire de Thérapie Génique, Nantes, France) and ml tri-iodothyronin, 5 µg/ml insulin, and 60 ng/ml prohad titers of 2.0tiimx10 11 , 7.0 × 10 11 , and 4.2 × 10 11 viral gesterone at 37°C and 5% CO 2 in a humidified atmoparticles per milliliter, respectively. sphere with three changes of medium a week. All supplements were from Sigma.
Animals
At the indicated time points, tissue was washed in Adult female Wistar rats of ϳ200 g (Charles River, PBS at 37°C for 15 min, fixed in 4% paraformaldehyde France) were housed three to four in a cage with free in 0.1 M phosphate buffer at 37°C for 15 min. The fragaccess to rat chow and water during a 12-h light/dark ments were then rinsed in PBS, mounted on slides using cycle.
Vectashield mounting fluid (Vector laboratories, Burl-The housing and treatment of the animals were peringame, CA, USA), and observed under fluorescence formed according to rules set by the Ethical Committee microscope to detect native GFP fluorescence. for Use of Laboratory Animals at ULB. Stereotaxy Rat embryos were obtained from pregnant Wistar rats (Charles River, France) at 15 days of gestation. The
The animals were anesthetized with a mixture of ketamin (50 mg/ml, Ketalar) and xylazine hydrochlorid pregnant dam was terminally anesthetized with a mixture of ketamine (Ketalar 50 mg/ml) and xylazin (23 mg/ml Rompun 2%). After anesthesia, animals were placed into stereotaxic frames (Kopf). All injec-(Rompun 2% 23 mg/ml, Bayer), and the uterine horns were removed by caesarian section and collected in tions were made using a 10-µl Hamilton microsyringe that was attached to a motorized injection system (Na-Hank's balanced salt solution (HBSS; Life Technology, USA).
noinjector, Stoelting) according to coordinates defined by Paxinos and Watson (22) . Experiments were ap-serum; five washings in TBS containing 0.1% Triton X-100 were performed between each step; (v) cell nuclei proved by the local committee for animal care (Commission d'éthique du bien-être animal, ULB).
were stained with a nuclear dye, Hoechst 33258, to reveal all the grafted cells. Sections were then mounted on Cell Suspensions. The anterio-posterior (AP) and gelatin-coated slides and coverslipped with FluorSave medial-lateral (ML) stereotaxic coordinates (AP: +0.5, reagent (Calbiochem, La Jolla, CA, USA). ML: −2.5) were calculated from bregma. A burr hole was drilled in the skull. The dorso-ventral (DV: −5.5/ Immunohistochemistry −4.5) coordinates were calculated from dural surface.
For GFP stainings, vibratome sections (50 µm) were All animals received two injections of 2 µl of embryonic sequentially incubated in: (i) 3% H 2 O 2 in TBS (Tris 10 day 15-infected striatal cells. The injection rate was 0.2 mM, 0.9% NaCl, pH 7.6) for 30 min; (ii) THST (50 mM µl/min in the striatum. One minute after the cessation of Tris, 0.5 M NaCl, 0.5% Triton X-100, pH 7.6) containthe infusion, the needle was retracted 1 mm and left in ing 10% horse serum for 1 h; (iii) polyclonal rabbit antiplace for an additional 2 min before it was slowly re-GFP (Clonetech, Palo Alto, CA, USA) diluted 1:3000 in tracted from the brain. Animals were sacrificed 2 months THST containing 5% horse serum overnight at 4°C; (iv) posttransplantation.
donkey anti rabbit-biotin (Amersham, Belgium) 1:600 in Recombinant Viruses. Viral particles diluted in D-THST containing 5% horse serum, 2 h at room tempera-PBS (BioWittaker) were infused using a motor-driven ture. The peroxidase staining was revealed using the Hamilton syringe (0.2 µl/min) with a 30-gauge needle.
ABC Elite vectastain kit and diaminobenzidine (Vector, The injection coordinates were, respectively, AP +;0.5 , NTL Laboratories, Brussels, Belgium), according to the L −2.8 , DV −5.0 for AAV2/1 (one deposit of 2 µl); AP manufacturer's protocol. Sections were mounted on gel-+0.7, L −3.5, DV −4.0, −5.0, and −6.0 (three deposits of atin-coated slides, dehydrated, and mounted using DPX 1 µl) for AAV2/2; and AP +0.5, L −2.8, DV −4.5 and mounting fluid (Sigma). Sections were photographed us-−5.5 for AAV2/5 (two deposits of 1 µl). After injection, ing a Zeiss Axiophot 2 microscope. the needle was left in place for 5 min in order to allow Optical Microscopy diffusion of the viral suspension in the parenchyma. The needle was then slowly lifted 1 mm up and left in place Cells harboring native GFP green fluorescence were 5 min, then slowly removed. Animals were sacrificed 1 evidenced using a Zeiss Axioplan II microscope equipped month after surgery.
with an UV lamp and a FITC filter. Images were acquired using the KS300 software (Zeiss).
Immunofluorescence
Confocal Microscopy Rats were anesthetized with a mixture of ketamin (50 Cell counts of immunopositive cells stained for GFP, mg/ml, Ketalar) and xylazine hydrochlorid (23 mg/ml NeuN, and GFAP were performed on six sections cover-Rompun 2%) and transcardially perfused with physioing the graft site using an automatic image analysis syslogical saline followed by 4% paraformaldehyde in 0.1 tem [Lasersharp version 3.2 (Biorad) coupled to Axiov-M phosphate buffer (PF4). Brains were removed and ert 100 microscope, Zeiss, Germany]. postfixed overnight in PF4 at 4°C. Coronal sections
To determine the proportion of GFP-expressing cells were cut using a vibratome (Leica) at 50 µm and labeled in the graft, the number of GFP-immunoreactive cells by immunofluorescence as follows.
was divided by the total number of cells revealed by Sections were sequentially incubated in: (i) THST Hoechst staining in each section. The double-labeled tis-[50 mM Tris, 0.5M NaCl, 0.5% Triton X-100 (Merck) sue was used to determine the percentage of GFP-immu-pH 7.6] containing 10% horse serum (Gibco BRL, Life noreactive cells that were labeled for NeuN or GFAP in Technologies, Belgium) for 30 min; (ii) mouse monothe grafts. To investigate the ability of gene transfer by three serotypes of AAV vectors (AAV2/2, -2/1, and -2/5) into West Grove, PA) diluted 1:100 in TBS containing 0.1% Triton X-100 and 5% horse serum for 2 h at room tem-embryonic GE tissue, we incubated solid fragments from 8 to 10 rat embryonic GE with 10 9 viral particles perature; (iv) streptavidin-cyanine 2 and donkey antimouse coupled to cyanine3 (both 1:100; Jackson Immuno of (i) rAAV2/1-eGFP, (ii) rAAV2/2-eGFP, and (iii) rAAV2/5-eGFP, and maintained them in organotypic Research, West Grove PA) in TBS containing 5% horse culture. After rAAV2/1-eGFP infection, cells started to phology were observed (Fig. 3) . No GFP-immunoreactive cells were observed in control animals (with non-express GFP as early as 4 days postinfection (data not shown) and their number increased up to at least 4 infected grafts; data not shown). The proportion of GFP-immunoreactive cells in the graft, as evaluated by weeks postinfection (Fig. 1A, D) . In contrast, after rAAV2/2-eGFP infection, only a few cells expressed co-staining with Hoechst, was 22 ± 0.2% (n = 4). GFP after 7 days and 4 weeks postinfection (Fig. 1B, Characterization of Transducted Cells E). In contrast, surprisingly, no green fluorescent cells were observed after rAAV2/5-eGFP infection (Fig. 1C , In all animals, the vast majority (93.6 ± 1.6%) (n = 4) of GFP-immunoreactive cells in the graft colabeled F). The rAAV-eGFP viral preparations were also evaluated in the adult rat striatum (Fig. 2) . Confirming previ-with NeuN ( Fig. 4A-C) . No colabeling (<2%) with the astrocytic GFAP marker was observed ( Fig. 4D-F) . ous studies (6), rAAV2/1-and rAAV2/5-mediated gene transfer was efficient and widespread ( Fig. 2A, C) DISCUSSION whereas in the case of rAAV2/2, the transduced area was limited to the vicinity of the needle tract (Fig. 2B) .
HD is an autosomal dominant disorder caused by an expanded polyglutamine (CAG) tract at the IT15 locus AAV2/1-Mediated Transgene Expression on chromosome 4 causing degeneration of striatal and in Transplanted Rat GE cortical neurons with severe motor and cognitive consequences. There is currently no treatment that can halt Embryonic rat GE fragments were incubated in rAAV2/1-EGFP viral suspension (10 9 viral particles per the progression of this disease. Fetal striatal transplants are currently explored as a novel therapeutic approach. 6 GE) for 2 h at 4°C, pooled, and trypsinized for 20 min at 37°C after infection. Animals received 4 µl of cells/ Grafts of embryonic GE survive long term in the diseased brain, induce significant and lasting motor and rat unilaterally into the right striatum. The cell viability before transplantation was more than 95% (data not cognitive therapeutic effects (4), and improve cortical metabolism (10). An autopsy study has suggested that shown). Two months after transplantation, the graft was well integrated. GFP-positive cells with a neuronal mor-the disease does not affect the transplanted cells that lack the mutant huntingtin gene (11). In contrast, the expression in vivo in various anatomical regions of the adult CNS without toxicity and with limited immune re-graft might not provide protection of host striatal neurons. Accordingly, patients who initially benefited from sponse to viral capsids.
In this report, we demonstrated that rAAV2/1 vectors fetal striatal grafts declined at 6 years posttransplantation (4). Therefore, neuroprotection might reinforce the efficiently transduce rat striatal cells for at least 4 weeks postinfection in vitro in organotypic cultures. We further-therapeutic effect of cell transplantation in HD. Furthermore, HD is a good candidate for neuroprotection be-more showed that gene transfer efficiency of rAAV2/1 is higher than rAAV2/2 and that rAAV2/5 does not trans-cause HD patients can be identified prior to the onset of neuronal degeneration and functional decline. Knowing duce fetal GE. These results are in striking contrast with the relative transduction efficiencies of adult rat striatum a patient's genetic profile could allow therapy to be applied before the initial anatomical changes occur and be-by these three serotypes (rAAV2/1 Х rAAV2/5 > rAAV2/ 2) [(6); our data]. This discrepancy could possibly be havioral sequelae appear.
Recent studies in animal models have shown that vi-due to a differential expression of AAV type 5 receptor or co-receptor (8,32) in adult and fetal striatum. rally mediated gene transfer could be a powerful means by which NF can be delivered to the central nervous After grafting of rAAV2/1-infected rat striatal fetal cells in the rat striatum, transgene expression was effi-system over long periods. Several vectors, including rAAV (7), lentiviral (14), and adenoviral vectors (18) , cient (more than 20% of the cells expressed the eGFP transgene) and stable (up to 2 months posttransplanta-have allowed the efficient transfer of genes to cells of the CNS. In contrast to other gene delivery systems, tion). Therefore, rAAV2/1-transduced grafts could be used as a stable cellular vector to deliver beneficial fac-rAAVs lack all viral genes and show long-term gene 
